Equity
€673,541 ▲ 16.0%
DEVA PHARMA has made a profit in every financial year since 2013.
DEVA PHARMA
Lifetime
13 annual accounts with figures on one time axispeak €159,432 (2023)
€143,510▲ 35.2%
peak €102,411 (2023)
€93,689▲ 44.0%
peak €673,541 (2025)
€673,541▲ 16.0%
€349,353▼ 12.2%
Board1 name since 2021
1 directorMuriel DEBEUCKELAERE
Documentsfilings and deeds
29-06-202632 days before the deadline
2025abbreviated format
Gross margin from €106,144 to €143,510Result from €65,053 to €93,689Dividend €1,000Equity from €580,852 to €673,541Cash from €67,754 to €118,740
Key points
from the 2025 annual accountsTurnover
≈ €220,000 estimated
The abbreviated format states no turnover.
Filings
13 annual accounts since 2013
The last five annual accounts were filed 20 to 32 days before the end of the period.
Financial institution: outside the modelBankruptcy probability: sector outside the model
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal, which does not raise the risk
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
32 days early
2024
30 days early
2023
29 days early
2022
28 days early
2021
20 days early
2020
25 days early
2019
25 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 27 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0847315091
Change of role: Muriel DEBEUCKELAERE, from manager to director
Director discharge: Muriel DEBEUCKELAERE · General meeting of 25-01-2024 · Gazette deed
First establishment
Baron van der Bruggenlaan 12, Wielsbeke
Incorporation
published on 23-07-2012 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DEVA PHARMA Wielsbeke | €1.0m | €143,510 | 65.7% | - |
| TJK INVEST Bredene | €1.1m | €148,303 | 22.6% | - |
| LV VENDO Pittem | €1.2m | €154,641 | 78.4% | - |
| HOLLEVOET INVEST Veurne | €0.9m | €122,329 | 25.3% | - |
| Endeavour Holdings Bruges | €1.0m | €138,744 | 16.0% | - |
| People Of Cameleon Ostend | €1.2m | €135,240 | 21.9% | - |
| OSCAR ALFA Bredene | €1.0m | €128,970 | 66.5% | - |
These companies have the same main activity as DEVA PHARMA: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €935,000 and €1.2m, founded between 2010 and 2013.
Official details
Source: KBO- Status
- Active since 03-07-2012Normal situation
- Activity
- Activities of holding companiesNACE 64210
- Establishment unit
- 2.211.125.3918710 Wielsbeke, since 10-07-2012
- Financial year end
- 31 December
- Peppol
- Reachable since 30-09-2025
Annual accounts 2025
- €1.0m▲ 4.5%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on DEVA PHARMA
DEVA PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €100,385 in 2013 to €143,510 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DEVA PHARMA
- What is the company number of DEVA PHARMA?
- The company number of DEVA PHARMA is 0847.315.091. The VAT number is the same number with BE in front: BE 0847.315.091.
- Where is DEVA PHARMA based?
- The registered office is at Ridder de Ghellinckstraat 28, 8710 Wielsbeke.Company details
- What does DEVA PHARMA do?
- According to the KBO register, the main activity is activities of holding companies (NACE 64210).
- What is the legal form of DEVA PHARMA?
- DEVA PHARMA is a private limited company (BV).
- When was DEVA PHARMA founded?
- DEVA PHARMA was founded on 03-07-2012.
- Is DEVA PHARMA still active?
- Yes, DEVA PHARMA is an active enterprise in the KBO register.
- What is the turnover of DEVA PHARMA?
- The turnover in financial year 2025 is ≈ €220,000. This figure is estimated from the gross margin of €143,510 and 32 comparable companies (NACE 64210). It probably lies between €190,000 and €280,000.Financials
- Is DEVA PHARMA profitable?
- In financial year 2025, DEVA PHARMA made a profit of €93,689.
- Where can I find the annual accounts of DEVA PHARMA?
- DEVA PHARMA filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DEVA PHARMA due?
- DEVA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See what changed in the latest annual accounts.What changed See this company's board, registered office and name on a given date.Company as of a date
See how customers, suppliers and banks see your own company and what to improve first.